What's new

RSS
Date Content
28/06/2019 Human medicines European public assessment report (EPAR): Adasuve, loxapine, Schizophrenia, Bipolar Disorder, 20/02/2013, 12, Authorised (updated)
28/06/2019 Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic, 27/09/2017, Additional monitoring, 4, Authorised (updated)
28/06/2019 Periodic safety update single assessment: Meningococcal group c polysaccharide conjugate vaccine: List of nationally authorised medicinal products - PSUSA/00001971/201810
28/06/2019 Orphan designation: PEGylated recombinant factor VIII (turoctocog alfa pegol) for the: Treatment of haemophilia A, 26/04/2012, Withdrawn (updated)
28/06/2019 Human medicines European public assessment report (EPAR): Esperoct, Turoctocog alfa pegol, Hemophilia A, 20/06/2019, Additional monitoring, Authorised
28/06/2019 Periodic safety update single assessment: Didanosine: List of nationally authorised medicinal products - PSUSA/00001054/201810
28/06/2019 Other: Annual list of specific contracts based on framework contracts – 2018
28/06/2019 Stem cell-based products for veterinary use: Specific questions on extraneous agents to be addressed by Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) (updated)
28/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Complex of povidone and iodine,dexamethasone (SHP640), PM: decision on the application for modification of an agreed PIP, P/0369/2018 (updated)
28/06/2019 Product-information templates (updated)
28/06/2019 Other: Annual list of contractors 2018 - contract values Euro 15,000 - 134.999
28/06/2019 Other: Annual list of contract modifications 2018
28/06/2019 PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision: Complex Povidone-Iodine and Dexamethasone (SHP640) - Notification of discontinuation of a paediatric development which is covered by an agreed paediatric-investigation-plan decision
28/06/2019 Procurement activities 2018 (updated)
28/06/2019 Stem cell-based products for veterinary use: specific questions on sterility to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) (updated)
28/06/2019 Orphan designation: copper meso-5,15-bis[3-[(1,2-dicarba-closo-dodecaboranyl)methoxy]phenyl]-meso-10,20-dinitroporphyrin for the: Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy, 27/06/2013, Positive (updated)
28/06/2019 Orphan designation: melatonin for the: Treatment of perinatal asphyxia, 11/01/2019, Positive (updated)
28/06/2019 Summary of opinion: Edistride, dapagliflozin, 27/06/2019, Positive
28/06/2019 Summary of opinion: Tecentriq, atezolizumab, 27/06/2019, Positive
28/06/2019 Annex to CHMP highlights: Start of union reviews adopted during the CHMP meeting 24 - 27 June 2019
28/06/2019 Summary of opinion: Ebymect, dapagliflozin / metformin, 27/06/2019, Positive
28/06/2019 Summary of opinion: Xyndari, glutamine, 29/05/2019, Negative (updated)
28/06/2019 Summary of opinion: Lacosamide UCB, lacosamide, 27/06/2019, Positive
28/06/2019 News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019
28/06/2019 Annex to CHMP highlights: Overview of (invented) names reviewed in May 2019 by the Name Review Group (NRG) Adopted at the CHMP meeting of 24-27 June 2019
28/06/2019 Summary of opinion: Azacitidine Celgene, azacitidine, 27/06/2019, Positive
28/06/2019 Summary of opinion: Giapreza, angiotensin II, 27/06/2019, Positive
28/06/2019 Summary of opinion: Forxiga, dapagliflozin, 27/06/2019, Positive
28/06/2019 Summary of opinion: Xigduo, dapagliflozin / metformin, 27/06/2019, Positive
28/06/2019 Summary of opinion: Victoza, liraglutide, 27/06/2019, Positive
28/06/2019 Summary of opinion: Imbruvica, ibrutinib, 28/06/2019, Positive
28/06/2019 Summary of opinion: Dupixent, dupilumab, 27/06/2019, Positive
28/06/2019 Summary of opinion: Flebogamma DIF (previously Flebogammadif), human normal immunoglobulin, 27/06/2019, Positive
28/06/2019 News and press releases: Bacterial lysate medicines for respiratory conditions to be used only for prevention of recurrent infections
28/06/2019 Summary of opinion: Evenity, romosozumab, 27/06/2019, Negative
28/06/2019 Summary of opinion: Cyramza, ramucirumab, 27/06/2019, Positive
28/06/2019 Referral: Bacterial lysates-containing medicinal products indicated for respiratory conditions , /Haemophilus influenzae / Klebsiella pneumoniae / Moraxella catarrhalis / Staphylococcus aureus / Streptococcus mitis / S. pneumoniae / S. pyogenes, H. influenzae / K. pneumoniae / M. catarrhalis / Staphylococcus aureus / Streptococcus pneumoniae / S. pyogenes, S. pneumoniae / S. agalactiae / Staphylococcus aureus / H. influenzae, H. influenzae / K. ozaenae / K. pneumoniae / M. catarrhalis / Staphylococcus aureus / Streptococcus pneumoniae / S. pyogenes / S. viridans, H. influenzae / membrane fraction of K. pneumoniae / ribosomal fractions of K. pneumoniae / S. pneumoniae / S. pyogenes, Escherichia coli / K. pneumoniae / S. aureus / S. epidermidis / S. salivarius / S. pneumoniae / S. pyogenes / H. influenzae / Corynebacterium pseudodiphtheriticum / M. catarrhalis/ , Article 31 referrals, Opinion provided by Committee for Medicinal Products for Human Use, 27/06/2019, 28/06/2019 (updated)
28/06/2019 Withdrawn application: ABP 710, infliximab, Date of withdrawal: 27/05/2019, Initial authorisation
28/06/2019 Veterinary medicines European public assessment report (EPAR): Ingelvac PCV FLEX, porcine circovirus type 2 ORF2 protein, 24/05/2017, 2, Withdrawn (updated)
28/06/2019 Other: Member states contact points for review of national versions of the content of mobile scanning and other technologies (updated)
28/06/2019 News and press releases: New treatment for children with type 2 diabetes
28/06/2019 Regulatory and procedural guideline: Compilation of Quality Review of Documents decisions on stylistic matters in product information (updated)
28/06/2019 Template or form: QRD product-information annotated template (English) version 10.1 (updated)
28/06/2019 Template or form: QRD annex related to the Article-127a template (updated)
28/06/2019 Template or form: Appendix V - Adverse-drug-reaction reporting details (updated)
28/06/2019 Template or form: QRD annex IV standard positive template (updated)
28/06/2019 Template or form: QRD product-information template version 10.1 (updated)
28/06/2019 Other: List of official languages per country (updated)
28/06/2019 Template or form: QRD product-information annotated template (English) version 10.1 - highlighted (updated)
28/06/2019 Regulatory and procedural guideline: Appendix IV - Terms and abbreviations for batch number and expiry date to be used on the labelling of human medicinal products (updated)
28/06/2019 Template or form: QRD product-information template version 10.1 - highlighted
28/06/2019 Template or form: PSUSA nationally authorised products template (updated)
28/06/2019 Template or form: QRD PSUR annex IV template (updated)
28/06/2019 Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, 26/04/2019, Additional monitoring, Biosimilar, Authorised
28/06/2019 Template or form: QRD annex A template (updated)
28/06/2019 Template or form: QRD annex IV conditional positive template (updated)
28/06/2019 Template or form: QRD annex IV exceptional circumstances positive template (updated)
27/06/2019 News and press releases: One additional country to benefit from EU-US mutual recognition agreement for inspections
27/06/2019 Human medicines European public assessment report (EPAR): Ondexxya, andexanet alfa, Drug-Related Side Effects and Adverse Reactions, 26/04/2019, Additional monitoring, Authorised
27/06/2019 European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting , European Medicines Agency via Adobe Connect, from 19/02/2019 to 19/02/2019
27/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): 5-(4-Fluoro-1-benzothiophen-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-H][2,3]benzodiazepin-2-one (S44819), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0286/2017 (updated)
27/06/2019 Referral: Closantel , closantel , Article 35, European Commission final decision, 21/02/2019, 20/05/2019
27/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Dexxience, Betrixaban, PM: decision on the application for modification of an agreed PIP, P/0168/2018 (updated)
27/06/2019 Summary of opinion: Zinforo, ceftaroline fosamil, 27/06/2019, Positive
27/06/2019 Human medicines European public assessment report (EPAR): Macugen, pegaptanib, Wet Macular Degeneration, 31/01/2006, 15, Withdrawn (updated)
27/06/2019 Human medicines European public assessment report (EPAR): Levitra, vardenafil, Erectile Dysfunction, 06/03/2003, 29, Authorised (updated)
26/06/2019 Human medicines European public assessment report (EPAR): Zoledronic Acid Hospira, zoledronic acid monohydrate, Hypercalcemia, 19/11/2012, Generic, 15, Authorised (updated)
26/06/2019 Human medicines European public assessment report (EPAR): Skyrizi, Risankizumab, Psoriasis, 26/04/2019, Additional monitoring, Authorised
26/06/2019 Human medicines European public assessment report (EPAR): Ferriprox, Deferiprone, beta-Thalassemia, Iron Overload, 25/08/1999, 24, Authorised (updated)
26/06/2019 Human medicines European public assessment report (EPAR): Tafinlar, dabrafenib mesylate, Melanoma, 26/08/2013, 20, Authorised (updated)
26/06/2019 Regulatory and procedural guideline: Detailed guide regarding the monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - Addendum 1
26/06/2019 Human medicines European public assessment report (EPAR): Zepatier, elbasvir, grazoprevir, Hepatitis C, Chronic, 22/07/2016, Additional monitoring, 7, Authorised (updated)
26/06/2019 Medicines under additional monitoring: Annex I - List of cyproterone-acetate / ethinylestradiol-containing medicinal products in the European Union (updated)
26/06/2019 Medicines under additional monitoring: Annex I - List of cyproterone-acetate / ethinylestradiol-containing medicinal products in the European Union (updated)
26/06/2019 Medicines under additional monitoring: Annex XIV – retinoid containing medicinal products and related substances (acitretin, alitretinoin, isotretinoin) (updated)
26/06/2019 Medicines under additional monitoring: Annex XIV – retinoid containing medicinal products and related substances (acitretin, alitretinoin, isotretinoin) (updated)
26/06/2019 Medicine for use outside EU: List of medicinal products under additional monitoring (updated)
26/06/2019 Medicines under additional monitoring: List of medicinal products under additional monitoring (updated)
26/06/2019 Referral: Fenspiride containing medicinal products , fenspiride , Article 107i procedures, Position provided by CMDh, 29/05/2019, 26/06/2019 (updated)
26/06/2019 List of medicines under additional monitoring (updated)
26/06/2019 Medicines under additional monitoring: Annex XIII - List of Valproate and related substances in the European Union (updated)
26/06/2019 Medicines under additional monitoring: Annex XIII - List of Valproate and related substances in the European Union (updated)
26/06/2019 Agenda: Agenda - PDCO agenda of the 25-28 June 2019 meeting
26/06/2019 Human medicines European public assessment report (EPAR): Inlyta, axitinib, Carcinoma, Renal Cell, 03/09/2012, 10, Authorised (updated)
26/06/2019 Human medicines European public assessment report (EPAR): Moventig, naloxegol oxalate, Constipation, Opioid-Related Disorders, 07/12/2014, Additional monitoring, 9, Authorised (updated)
26/06/2019 Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, 08/01/2018, Additional monitoring, 4, Authorised (updated)
26/06/2019 Human medicines European public assessment report (EPAR): Zejula, niraparib tosylate monohydrate, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, 16/11/2017, Orphan, Additional monitoring, 5, Authorised (updated)
26/06/2019 Human medicines European public assessment report (EPAR): Mekinist, trametinib, Melanoma, 30/06/2014, 17, Authorised (updated)
25/06/2019 Human medicines European public assessment report (EPAR): Spinraza, nusinersen sodium, Muscular Atrophy, Spinal, 30/05/2017, Orphan, Additional monitoring, 7, Authorised (updated)
25/06/2019 Human medicines European public assessment report (EPAR): Bavencio, avelumab, Neuroendocrine Tumors, 18/09/2017, Orphan, Additional monitoring, Conditional approval, 4, Authorised (updated)
25/06/2019 Referral: Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group , valsartan, candesartan, irbesartan, losartan and olmesartan , Article 31 referrals, European Commission final decision, 31/01/2019, 02/04/2019, 25/06/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Chemically modified extract of trees pollen from birch and alder, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0086/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Chemically modified house dust mites allergen extract (Dermatophagoides pteronyssinus and Dermatophagoides farinae), RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0087/2019 (updated)
25/06/2019 Other: Temporary interim limits for NMBA, DIPNA and EIPNA impurities in sartan blood pressure medicines
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Uptravi, Selexipag, PM: decision on the application for modification of an agreed PIP, P/0123/2019 (updated)
25/06/2019 Human medicines European public assessment report (EPAR): Defitelio, defibrotide, Hepatic Veno-Occlusive Disease, 18/10/2013, Orphan, Additional monitoring, Exceptional circumstances, 8, Authorised (updated)
25/06/2019 Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Peripheral Vascular Diseases, Acute Coronary Syndrome, 03/12/2010, 13, Authorised (updated)
25/06/2019 Orphan designation: Tazemetostat for the: Treatment of diffuse large B-cell lymphoma, 21/03/2018, Positive (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Refixia, Nonacog beta pegol, PM: decision on the application for modification of an agreed PIP, P/0139/2019 (updated)
25/06/2019 Support for advanced-therapy developers (updated)
25/06/2019 Guidance on good manufacturing practice and good distribution practice: Questions and answers (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, PM: decision on the application for modification of an agreed PIP, P/0080/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, PM: decision on the application for modification of an agreed PIP, P/0071/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, PM: decision on the application for modification of an agreed PIP, P/0134/2019 (updated)
25/06/2019 Human medicines European public assessment report (EPAR): Isentress, Raltegravir, HIV Infections, 19/12/2007, 36, Authorised (updated)
25/06/2019 Orphan designation: Tazemetostat for the: Treatment of follicular lymphoma, 21/03/2018, Positive (updated)
25/06/2019 Orphan designation: Tazemetostat for the: Treatment of malignant mesothelioma, 21/03/2018, Positive (updated)
25/06/2019 Human medicines European public assessment report (EPAR): Doptelet, avatrombopag, Thrombocytopenia, Additional monitoring, Authorised (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Stivarga, regorafenib, PM: decision on the application for modification of an agreed PIP, P/0158/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Mekinist, Trametinib (dimethyl sulfoxide), PM: decision on the application for modification of an agreed PIP, P/0076/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Onasemnogenum abeparvovecum, PM: decision on the application for modification of an agreed PIP, P/0162/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Lefamulin, PM: decision on the application for modification of an agreed PIP, P/0066/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Carotuximab, PM: decision on the application for modification of an agreed PIP, P/0072/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Avalglucosidase alfa, PM: decision on the application for modification of an agreed PIP, P/0073/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): 3-[[5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)-1,3-dihydro-3-[[5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridine-2-one (JNJ-53718678), PM: decision on the application for modification of an agreed PIP, P/0081/2019 (updated)
25/06/2019 Patients' and Consumers' Working Party (updated)
25/06/2019 Eligible patients and consumers organisations (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Tralokinumab, PM: decision on the application for modification of an agreed PIP, P/0104/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Emgality, Galcanezumab, PM: decision on the application for modification of an agreed PIP, P/0111/2019 (updated)
25/06/2019 Report: Medicinal products for human use: monthly figures - May 2019
25/06/2019 Minutes: Minutes of the CHMP meeting 23-26 April 2019
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Inebilizumab, PM: decision on the application for modification of an agreed PIP, P/0129/2019 (updated)
25/06/2019 Other: Questions and answers on the use of out-of-specification batches of authorised cell and tissue-based advanced therapy medicinal products
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Angiotensin II (LJPC-501), PM: decision on the application for modification of an agreed PIP, P/0159/2019 (updated)
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Oxervate, Cenegermin, W: decision granting a waiver in all age groups for all conditions/indications, P/0118/2019
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Multivalent, live, recombinant, non-replicating in human cells, Modified Vaccinia Ankara vectored vaccine, expressing the EBOV Mayinga glycoprotein, the Sudan virus Gulu GP, the Marburg virus Musoke GP, and the Taï Forest virus nucleoprotein [MVA-BN-Filo], P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0117/2019
25/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Monovalent, live, recombinant, replication-incompetent adenoviral serotype 26 vectored vaccine expressing the full length glycoprotein of the Ebola virus Mayinga variant [Ad26.ZEBOV], P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0116/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Tafinlar, Dabrafenib (mesilate), PM: decision on the application for modification of an agreed PIP, P/0065/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Zerbaxa, Ceftolozane,tazobactam, PM: decision on the application for modification of an agreed PIP, P/0154/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Plegridy, peginterferon beta-1a, PM: decision on the application for modification of an agreed PIP, P/0067/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Autologous cartilage derived cultured chondrocytes, PM: decision on the application for modification of an agreed PIP, P/0074/2019 (updated)
24/06/2019 Committee meeting report: PDCO monthly report of opinions on paediatric investigation plans and other activities 27-29 May 2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Humanised anti-IL-6 receptor (IL-6R) monoclonal antibody, PM: decision on the application for modification of an agreed PIP, P/0061/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Peanut flour, PM: decision on the application for modification of an agreed PIP, P/0114/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Upadacitinib (ABT-494), PM: decision on the application for modification of an agreed PIP, P/0068/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Upadacitinib (ABT-494), PM: decision on the application for modification of an agreed PIP, P/0069/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily A; Escherichia coli),Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily B; Escherichia coli), PM: decision on the application for modification of an agreed PIP, P/0098/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Quizartinib, PM: decision on the application for modification of an agreed PIP, P/0163/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0083/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Maviret, glecaprevir,pibrentasvir, PM: decision on the application for modification of an agreed PIP, P/0128/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0084/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Chemically modified house dust mites allergen extract (Dermatophagoides pteronyssinus and Dermatophagoides farinae), RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0101/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, PM: decision on the application for modification of an agreed PIP, P/0107/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Vemlidy, Tenofovir alafenamide (as fumarate), PM: decision on the application for modification of an agreed PIP, P/0133/2019 (updated)
24/06/2019 Careers (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Chemically modified extract of trees pollen from birch and alder, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0085/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, PM: decision on the application for modification of an agreed PIP, P/0141/2019 (updated)
24/06/2019 Veterinary medicines European public assessment report (EPAR): Recocam, meloxicam, 13/09/2011, Generic, 5, Authorised (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Molgramostim, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0094/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Natpar, Recombinant parathyroid hormone, PM: decision on the application for modification of an agreed PIP, P/0136/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Luspatercept, PM: decision on the application for modification of an agreed PIP, P/0130/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Fevipiprant, RP: decision refers to a refusal on a proposed Paediatric Investigation Plan, P/0157/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Acalabrutinib, PM: decision on the application for modification of an agreed PIP, P/0062/2019 (updated)
24/06/2019 Human medicines European public assessment report (EPAR): Telzir, fosamprenavir calcium, HIV Infections, 12/07/2004, 41, Authorised (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Lartruvo, Olaratumab, W: decision granting a waiver in all age groups for all conditions/indications, P/0112/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Cresemba, Isavuconazonium (sulfate), PM: decision on the application for modification of an agreed PIP, P/0100/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Praxbind, idarucizumab, PM: decision on the application for modification of an agreed PIP, P/0151/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Orbactiv, Oritavancin (diphosphate), PM: decision on the application for modification of an agreed PIP, P/0131/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Voclosporin, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0152/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Galafold, Migalastat (hydrochloride), PM: decision on the application for modification of an agreed PIP, P/0137/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): 177Lu-PSMA-617, W: decision granting a waiver in all age groups for all conditions/indications, P/0127/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Recombinant Influenza Hemagglutinin-strain A (H1N1 subtype) / Recombinant Influenza Hemagglutinin-strain A (H3N2 subtype) / Recombinant Influenza Hemagglutinin-strain B (Victoria lineage) / Recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) (RIV4), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0088/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Ridinilazole, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0109/2019
24/06/2019 Agenda: Agenda - CHMP agenda of the 24-27 June 2019 meeting
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Oteseconazole, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0147/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Chemically modified recombinant human sulfamidase, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0113/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Liposomal vinorelbine (tartrate), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0155/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): N-hydroxy-5-methylfuran-2-sulfonamide (BMS-986231), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0110/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): 1-{[(2S,3S)-2-carboxylato-3-methyl-4,4,7-trioxo-4-{6}-thia-1-azabi-cyclo[3.2.0]heptan-3- yl]methyl}-3-methyl-1H-1,2,3-triazol-3-ium (AAI101), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0093/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Orvepitant, W: decision granting a waiver in all age groups for all conditions/indications, P/0119/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Rosuvastatin (calcium) / fenofibrate, W: decision granting a waiver in all age groups for all conditions/indications, P/0120/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): N2’-Deacetyl-N2’-[4-methyl-4-(oxobutyldithio)-1-oxopentyl]-maytansine-hu769_4D4 Antibody, W: decision granting a waiver in all age groups for all conditions/indications, P/0132/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Mavacamten, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0106/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Anti-IL-21 humanized immunoglobulin G1-kappa monoclonal antibody (BOS161721), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0148/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Serlopitant, W: decision granting a waiver in all age groups for all conditions/indications, P/0135/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains (bb2121), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0149/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): ivacaftor / tezacaftor/ potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide (VX-659), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0090/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Rivoceranib (mesylate), W: decision granting a waiver in all age groups for all conditions/indications, P/0140/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Tislelizumab, W: decision granting a waiver in all age groups for all conditions/indications, P/0142/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): (R)-azasetron (besylate) (SENS-401), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0105/2019
24/06/2019 Veterinary medicines European public assessment report (EPAR): ProZinc, insulin human, 12/07/2013, 8, Authorised (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl) acetamide (KX2-391), W: decision granting a waiver in all age groups for all conditions/indications, P/0075/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Dihomo-γ-linolenic acid (DS107), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0102/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Pyrimidinyl-aminopyridine dual leucine zipper kinase inhibitor (GDC-0134), RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s), P/0099/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Spartalizumab, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0089/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Genetically modified Mycobacterium bovis BCG, W: decision granting a waiver in all age groups for all conditions/indications, P/0078/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H- benzo[c]chromene-9-carboxylic acid (lenabasum), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0095/2019
24/06/2019 Human medicines European public assessment report (EPAR): Caspofungin Accord, caspofungin acetate, Candidiasis, Aspergillosis, 11/02/2016, Generic, 5, Authorised (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Rosuvastatin (calcium),Amlodipine (besylate), W: decision granting a waiver in all age groups for all conditions/indications, P/0079/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Gadopiclenol, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0145/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemaciclib, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0124/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (VX-445) / tezacaftor / ivacaftor, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0091/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Inactivated patients own (autologous) microorganism (Escherichia coli, Candida spp., Enterococcus spp., Streptococcus spp., Staphylococcus spp., Prevotella intermedia, Fusobacterium nucleatum and others), W: decision granting a waiver in all age groups for all conditions/indications, P/0161/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Upadacitinib, W: decision granting a waiver in all age groups for all conditions/indications, P/0103/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Rogaratinib, W: decision granting a waiver in all age groups for all conditions/indications, P/0156/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Relugolix,estradiol,norethisterone acetate, W: decision granting a waiver in all age groups for all conditions/indications, P/0108/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): isoflurane, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0092/2019
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Vipidia, alogliptin, PM: decision on the application for modification of an agreed PIP, P/0097/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Volibris, ambrisentan, PM: decision on the application for modification of an agreed PIP, P/0077/2019 (updated)
24/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Xarelto, rivaroxaban, PM: decision on the application for modification of an agreed PIP, P/0126/2019 (updated)
21/06/2019 Healthcare Professionals' Working Party
21/06/2019 News and press releases: Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 18-20 June 2019
21/06/2019 Summary of opinion: Advocate, imidacloprid / moxidectin, 20/06/2019, Positive
21/06/2019 Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium bromide, Pulmonary Disease, Chronic Obstructive, 20/03/2017, Additional monitoring, 5, Authorised
21/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Methoxyflurane, PM: decision on the application for modification of an agreed PIP, P/0063/2019
21/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Stelara, Ustekinumab, PM: decision on the application for modification of an agreed PIP, P/0096/2019
21/06/2019 Human medicines European public assessment report (EPAR): Benepali, etanercept, Arthritis, Psoriatic, Arthritis, Rheumatoid, Psoriasis, 13/01/2016, Additional monitoring, Biosimilar, 8, Authorised
21/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): MabThera, rituximab, PM: decision on the application for modification of an agreed PIP, P/0064/2019
21/06/2019 Human medicines European public assessment report (EPAR): Docetaxel Accord, docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms, 22/05/2012, Generic, 12, Authorised
21/06/2019 Human medicines European public assessment report (EPAR): Gefitinib Mylan, gefitinib, Carcinoma, Non-Small-Cell Lung, 27/09/2018, Generic, 1, Authorised
21/06/2019 European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH) , European Medicines Agency, London, UK, from 03/12/2018 to 03/12/2018
21/06/2019 Report: Report - European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)
20/06/2019 Committee for Medicinal Products for Human Use (CHMP): 25-28 March 2019 , European Medicines Agency, from 25/03/2019 to 28/03/2019
20/06/2019 Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 March 2019 , European Medicines Agency, Amsterdam, the Netherlands, from 19/03/2019 to 21/03/2019
20/06/2019 Human medicines European public assessment report (EPAR): Vosevi, Sofosbuvir, velpatasvir, voxilaprevi, Hepatitis C, Chronic, 26/07/2017, Additional monitoring, 4, Authorised
20/06/2019 Veterinary medicines European public assessment report (EPAR): Vectra 3D, dinotefuran, pyriproxyfen, permethrin, 04/12/2013, 4, Authorised
20/06/2019 Committee meeting report: Monthly report on application procedures guidelines and related documents for veterinary medicines: March 2019
20/06/2019 Agenda: Agenda - CAT agenda of the 19-21 June 2019 meeting
20/06/2019 Minutes: CHMP ORGAM minutes for the meeting on 18 March 2019
20/06/2019 Agenda: CHMP ORGAM agenda for the meeting on 18 March 2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Elonva, corifollitropin alfa, PM: decision on the application for modification of an agreed PIP, P/0143/2019
20/06/2019 Periodic safety update single assessment: Methoxyflurane: List of nationally authorised medicinal products - PSUSA/00010484/201811
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Intelence, Etravirine, PM: decision on the application for modification of an agreed PIP, P/0121/2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Revolade, Eltrombopag, W: decision granting a waiver in all age groups for all conditions/indications, P/0070/2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Ozanimod, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0153/2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Delafloxacin, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0125/2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Ofev, nintedanib, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0150/2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Jardiance, empagliflozin, W: decision granting a waiver in all age groups for all conditions/indications, P/0082/2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab, W: decision granting a waiver in all age groups for all conditions/indications, P/0144/2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): L-Asparaginase, W: decision granting a waiver in all age groups for all conditions/indications, P/0138/2019
20/06/2019 Opinion/decision on a Paediatric investigation plan (PIP): Eylea, aflibercept, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0115/2019
20/06/2019 Human medicines European public assessment report (EPAR): MicardisPlus, telmisartan, hydrochlorothiazide, Hypertension, 19/04/2002, 27, Authorised
20/06/2019 Human medicines European public assessment report (EPAR): Halaven, Eribulin, Breast Neoplasms, Liposarcoma, 17/03/2011, 20, Authorised
20/06/2019 Human medicines European public assessment report (EPAR): Ilaris, Canakinumab, Cryopyrin-Associated Periodic Syndromes, Arthritis, Juvenile Rheumatoid, Arthritis, Gouty, 23/10/2009, 23, Authorised
19/06/2019 Veterinary medicines European public assessment report (EPAR): Cytopoint, lokivetmab, 25/04/2017, 3, Authorised
19/06/2019 Human medicines European public assessment report (EPAR): Ketek, telithromycin, Sinusitis, Tonsillitis, Bronchitis, Chronic, Pharyngitis, Community-Acquired Infections, Pneumonia, Bacterial, 09/07/2001, 25, Withdrawn
19/06/2019 Human medicines European public assessment report (EPAR): Veltassa, patiromer sorbitex calcium, Hyperkalemia, 19/07/2017, Additional monitoring, 1, Authorised
19/06/2019 Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive, 08/05/2014, Additional monitoring, 11, Authorised
19/06/2019 Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Breast Neoplasms, Pancreatic Neoplasms, Carcinoma, Non-Small-Cell Lung, 10/01/2008, 24, Authorised
19/06/2019 Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Anxiety Disorders, Epilepsy, 10/04/2014, 16, Authorised
19/06/2019 Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Epilepsy, Anxiety Disorders, Neuralgia, 05/07/2004, 42, Authorised
19/06/2019 Periodic safety update single assessment: Benzydamine: List of nationally authorised medicinal products - PSUSA/00000375/201810
19/06/2019 Periodic safety update single assessment: Ceftazidime: List of nationally authorised medicinal products - PSUSA/00000608/201810
19/06/2019 Periodic safety update single assessment: Azelastine / fluticasone: List of nationally authorised medicinal products - PSUSA/00010067/201810
19/06/2019 Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Diabetes Mellitus, Type 2, 23/08/2011, 12, Authorised
19/06/2019 Veterinary medicines European public assessment report (EPAR): Innovax-ND-IBD, Cell-associated live recombinant turkey herpesvirus (strain HVP360), expressing the fusion protein of ND virus and the VP2 protein of IBD virus, 22/08/2017, 1, Authorised
19/06/2019 Veterinary medicines European public assessment report (EPAR): Profender, emodepside, praziquantel, 27/07/2005, 17, Authorised
19/06/2019 Agenda: Agenda - CVMP agenda of the 18-20 June 2019 meeting
19/06/2019 Human medicines European public assessment report (EPAR): Steglatro, ertugliflozin l-pyroglutamic acid, Diabetes Mellitus, Type 2, 21/03/2018, Additional monitoring, 4, Authorised
19/06/2019 Referral: Septanest and associated names , articaine (hydrochloride) / adrenaline (tartrate) , Article 30 referrals, European Commission final decision, 28/06/2018, 28/03/2019, 19/06/2019